Trials / Completed
CompletedNCT01934010
AM-101 in the Treatment of Post-Acute Tinnitus 1
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Auris Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test the safety and local tolerance of repeated treatment cycles of AM-101.
Detailed description
This open-label extension study is assessing the safety and local tolerance of repeated treatment cycles of AM-101 in subjects previously treated in the scope of the TACTT2 study (NCT01803646).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AM-101 | AM-101 gel for intratympanic injection |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2013-09-04
- Last updated
- 2018-05-16
- Results posted
- 2018-03-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01934010. Inclusion in this directory is not an endorsement.